Loading company…
MethylGene develops targeted drugs for cancer and infectious diseases.
Founded in 1995 and based in Quebec, Canada, MethylGene develops targeted drugs for cancer and infectious diseases. Its work includes discovering and developing enzyme inhibitors for cancer treatment, using functional genomics, rational drug design, and medicinal chemistry. In November 2012, it closed a CAD 26.1 million private placement led by Tavistock Group, with BVF Partners, OrbiMed Advisors, RA Capital, and Tang Capital Management participating. The company was at the Public stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in